Candesartan CAS 139481-59-7 Puritas >99.0% (HPLC) Factory

Description:

Chemical Name: Candesartan

CAS: 139481-59-7

Puritas: >99.0% (HPLC)

Aspectus: pulveris albi

Angiotensin II Receptor Antagon

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Candesartan Cilexetil medium cum puritate
Candesartan Cilexetil CAS 145040-37-5
Candesartan CAS 139481-59-7
1-Chloroethyl Cyclohexyl Carbonatis CAS 99464-83-2
Candesartan Cilexetil Intermedia Eethyl Ester C6 CAS 139481-41-7
Candesartan Cilexetil Intermediate CAS 139481-44-0
Trityl Candesartan Cilexetil CAS 170791-09-0

Chemical Properties:

Nomen chemicum	Candesartan
Synonyma	CV-11974;2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-Carboxylic Acidum;3-[[2'-(1H-Tetrazol-5-yl) biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acidum;Candesartan M1;Candesartan Cilexetil EP
CAS Number	139481-59-7
CATTUS Number	RF-PI1889
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C24H20N6O3
M. Pondus	440.45
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba pulveris
Lepidium sativum-HPLC	Retentionis Tempus Similar to Latin
Lepidium sativum IR	Similes Latin
Puritas / Analysis Methodus	>99.0% (HPLC)
Liquescens punctum	183.0~ 185.0℃
Damnum in Siccatio	<0.50%
Humor (KF)	<0.50%
Residere in Ignition	<0.50%
Metalla gravis	<20ppm
Individual Impurity	<1.00% (HPLC)
Totalis immunditias	<1.00% (HPLC)
Index refractivus	n20/D 1.745~1.747
Test Standard	Enterprise Standard
Consuetudinem	API;Curatio Hypertension

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Candesartan (CAS: 139481-59-7) est angiotensin II receptor contra IC50 of 0.26 nM.Scopum: Angiotensin II Receptor candesartan indicatur pro curatione hypertensionis.Candesartan Cilexetil primum in GB die 29 Apr 1997 probatus est, deinde ab US Food and Drug Administration (FDA) die 4 Iunii 1998 probatus est, et a Pharmaceuticis et Medicis machinis Agency Iaponiae (PMDA) die 12 mar. AstraZeneca ab AstraZeneca evoluta est, tum Atacand ab AstraZeneca in GB et US venales, et ut Blopress ab Takeda in JP.Candesartan Cilexetil est angiotensin II receptaculum obstructorem (ARB), vasoconstrictorem et aldosterone-absconditum effectus angiotensin II impedit electe ligamen angiotensin II ad AT1 receptorem in multis fibris, ut vascularis musculi laevis et glandulae adrenalis.Atacand indicatur curationem hypertensionis in adultis et pueris 1 ad <17 annos natis, defectum cordis (NYHA classis II-IV) et ad mortem cardiovascularem reducendam et cor defectum hospitalizationis.